Clinical Trial Update: Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial from Fudan University is exploring heterogeneity in 68Ga-FAPI uptake as an imaging biomarker for brain metastases in HER2-positive breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Ga-68 FAPI imaging tracer (gallium-68 labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING